Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Articles
Insights
Vantage Data Points
Share Price Catalysts June 2019
July 03, 2019
Share price catalysts: June 2019
Edwin Elmhirst
Vantage Data Points
Related Companies
Acer Therapeutics
Aclaris Therapeutics
Adaptive Biotechnologies
InflaRx
La Jolla Pharmaceutical
Melinta Therapeutics
NovaBay Pharmaceuticals
Provention Bio
Savara Pharmaceuticals
VBI Vaccines
Download PDF
Share This Article
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 17, 2023
PD(L)anner – February 2023
February 09, 2023
Biopharma and Medtech Review 2022
Related Articles
December 22, 2022
Go or no go? Lecanemab’s destiny approaches
June 22, 2020
Tetraphase’s love quadrangle sees three bald men fight over a comb
November 04, 2019
Share price movers – October 2019
October 04, 2019
Japanese drugmakers stand out at the nine-month mark
March 13, 2023
Sanofi’s Provention buy could get other partners’ hopes up
